Turnstone Biologics files for IPO

Jun. 12, 2023 5:34 PM ETBy: Jonathan Block, SA News Editor

Turnstone Biologics, a biotech focused on treatments for solid tumors, has filed for an IPO.
The company intends to trade under the ticker "TSBX."
BofA, SVB, and Piper Sandler are acting as joint book-runners.
Turnstone's (TSBX) approach is to use tumor infiltrating lymphocytes, which the company says can help patients who don't respond well to current immunotherapies. According to Turnstone, these patients are challenged by the "low numbers of T cells that can recognize and attack the tumor, which we refer to as tumor-reactive T cells."
The company has one candidate in the clinic, TBio-4101, in phase 1 for breast cancer, colorectal cancer, and uveal melanoma, as well as cutaneous and non-cutaneous melanomas.